The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
The role of monoamines in the actions of established and “novel” antidepressant agents: a critical review
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression
Shirayama, Y., Chen, A. C.-H., Nakagawa, S., Russell, D. S., & Duman, R. S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03251.2002 · Cited by 1,654
Synthesis of Serotonin by a Second Tryptophan Hydroxylase Isoform
Walther, D. J., Peter, J.-U., Bashammakh, S., Hörtnagl, H., Voits, M., Fink, H., & Bader, M. (2003) · Science · doi:10.1126/science.1078197 · Cited by 1,570
Assessing antidepressant activity in rodents: recent developments and future needs
Cryan, J. F., Markou, A., & Lucki, I. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02017-5 · Cited by 1,551
The Economic Burden of Depression in the United States: How Did It Change Between 1990 and 2000?
Greenberg, P. E., Kessler, R. C., Birnbaum, H. G., Leong, S. A., Lowe, S. W., Berglund, P. A., & Corey-Lisle, P. K. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1211 · Cited by 1,280
Gold, P. W., & Chrousos, G. P. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001032 · Cited by 1,274
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 965
Self-citationAdult brain neurogenesis and psychiatry: a novel theory of depression
Jacobs, B. L., van Praag, H., & Gage, F. H. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000712 · Cited by 964
Anderson, I. M. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00092-0 · Cited by 940
Plasma membrane monoamine transporters: structure, regulation and function
Torres, G. E., Gainetdinov, R. R., & Caron, M. G. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1008 · Cited by 939
Malberg, J. E., & Duman, R. S. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300234 · Cited by 815
Zobel, A. W., Nickel, T., Künzel, H. E., Ackl, N., Sonntag, A., Ising, M., & Holsboer, F. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(00)00016-9 · Cited by 705
Bupropion: a review of its mechanism of antidepressant activity.
Ascher, J. A., Cole, J. O., Colin, J. N., Feighner, J. P., Ferris, R. M., Fibiger, H. C., Golden, R. N., Martin, P., Potter, W. Z., & Richelson, E. (1995) · PubMed · Cited by 680
Effects of adverse experiences for brain structure and function
McEwen, B. S. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00964-1 · Cited by 639
Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression
Reul, J. (2002) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00117-5 · Cited by 516
Millan, M. J., Gobert, A., Lejeune, F., Dekeyne, A., Newman-Tancredi, A., Pasteau, V., Rivet, J.-M., & Cussac, D. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.051797 · Cited by 516
Self-citationManji, H. K., Quiroz, J. A., Sporn, J., Payne, J. L., Denicoff, K., A. Gray, N., Zarate, C. A., & Charney, D. S. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00117-3 · Cited by 505
A Novel Augmentation Strategy for Treating Resistant Major Depression
Shelton, R. C., Tollefson, G. D., Tohen, M., Stahl, S., Gannon, K. S., Jacobs, T. G., Buras, W. R., Bymaster, F. P., Zhang, W., Spencer, K. A., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.1.131 · Cited by 504
Stahl, S. M. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0103 · Cited by 489
The neural substrates of affective processing in depressed patients treated with venlafaxine
Davidson, R. J., Irwin, W., Anderle, M. J., & Kalin, N. H. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.64 · Cited by 487
Sánchez, C., & Hyttel, J. (1999) · Cellular and Molecular Neurobiology · doi:10.1023/a:1006986824213 · Cited by 429
L??o, H., Hale, A., & D??haenen, H. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200209000-00004 · Cited by 361
Regulation of hippocampal synaptic plasticity by cyclic AMP-dependent protein kinases
Nguyen, P. V., & Woo, N. H. (2003) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2003.12.003 · Cited by 328
Newton, S. S., Thome, J., Wallace, T. L., Shirayama, Y., Schlesinger, L., Sakai, N., Chen, J., Neve, R., Nestler, E. J., & Duman, R. S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-24-10883.2002 · Cited by 313
Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4)
O'Donnell, J. M., & Zhang, H.-T. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.01.003 · Cited by 307
Woolley, M., Marsden, C., & Fone, K. (2004) · Current Drug Target -CNS & Neurological Disorders · doi:10.2174/1568007043482561 · Cited by 302
Rapid Reversal of Psychotic Depression Using Mifepristone
Belanoff, J. K., Flores, B. H., Kalezhan, M., Sund, B., & Schatzberg, A. F. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200110000-00009 · Cited by 282
A review of the role of serotonin receptors in psychiatric disorders
Naughton, M., Mulrooney, J. B., & Leonard, B. E. (2000) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/1099-1077(200008)15:6<397::aid-hup212>3.0.co;2-l · Cited by 258
Leysen, J. (2004) · Current Drug Target -CNS & Neurological Disorders · doi:10.2174/1568007043482598 · Cited by 249
Millan, M. J., Brocco, M., Gobert, A., & Dekeyne, A. (2005) · Psychopharmacology · doi:10.1007/s00213-004-1962-z · Cited by 248
Self-citationThe role of the brain reward system in depression
Naranjo, C. A., Tremblay, L. K., & Busto, U. E. (2001) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00156-7 · Cited by 245
The pharmacology of putative early-onset antidepressant strategies
Blier, P. (2003) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(02)00173-6 · Cited by 244
Millan, M. J., Lejeune, F., & Gobert, A. (2000) · Journal of Psychopharmacology · doi:10.1177/026988110001400202 · Cited by 231
Self-citationSvenningsson, P., Tzavara, E. T., Witkin, J. M., Fienberg, A. A., Nomikos, G. G., & Greengard, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052712799 · Cited by 230
Zhang, H. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00344-5 · Cited by 229
From monoamines to genomic targets: a paradigm shift for drug discovery in depression
Wong, M.-L., & Licinio, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1303 · Cited by 225
Maurice, T., Urani, A., Phan, V.-L., & Romieu, P. (2001) · Brain Research Reviews · doi:10.1016/s0165-0173(01)00112-6 · Cited by 223
Reagan, L. P., Rosell, D. R., Wood, G. E., Spedding, M., Muñoz, C., Rothstein, J., & McEwen, B. S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307294101 · Cited by 221
Schramm, N. L., McDonald, M. P., & Limbird, L. E. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-13-04875.2001 · Cited by 217
Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs
Joyce, J. N. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(01)00139-5 · Cited by 214
Mayorga, A. J., Dalvi, A., Page, M. E., Zimov-Levinson, S., Hen, R., & Lucki, I. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29479-9 · Cited by 209
Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction
Montgomery, S. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(01)00313-5 · Cited by 205
Thomas, D., & Hagan, J. (2004) · Current Drug Target -CNS & Neurological Disorders · doi:10.2174/1568007043482633 · Cited by 183
Hammack, S. E., Schmid, M. J., LoPresti, M. L., Der-Avakian, A., Pellymounter, M. A., Foster, A. C., Watkins, L. R., & Maier, S. F. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-03-01019.2003 · Cited by 176
Millan, M. J., Gobert, A., Rivet, J. ‐., Adhumeau‐Auclair, A., Cussac, D., Newman‐Tancredi, A., Dekeyne, A., Nicolas, J. ‐., & Lejeune, F. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00982.x · Cited by 170
Self-citationRogóż, Z., Skuza, G., Maj, J., & Danysz, W. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00055-2 · Cited by 169
Current Trends in the Development of New Antidepressants
Pacher, P., Kohegyi, E., Kecskemeti, V., & Furst, S. (2001) · Current Medicinal Chemistry · doi:10.2174/0929867013373796 · Cited by 160
van der Hart, M. G. C., Czéh, B., de Biurrun, G., Michaelis, T., Watanabe, T., Natt, O., Frahm, J., & Fuchs, E. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001130 · Cited by 158
Antidepressants: past, present and future
Vetulani, J., & Nalepa, I. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00565-3 · Cited by 158
Millan, M. J., Gobert, A., Lejeune, F., Newman‐Tancredi, A., Rivet, J., Auclair, A., & Péglion, J.-L. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29415-5 · Cited by 149
Self-citationAntidepressant-like behavioral effects of serotonin receptor agonists
Lucki, I., Singh, A., & Kreiss, D. S. (1994) · Neuroscience & Biobehavioral Reviews · doi:10.1016/0149-7634(94)90039-6 · Cited by 147
Elevated agonist binding to α2-adrenoceptors in the locus coeruleus in major depression
Ordway, G. A., Schenck, J. E., Stockmeier, C. A., May, W., & Klimek, V. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01728-6 · Cited by 145
Bai, F., Bergeron, M., & Nelson, D. L. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00104-7 · Cited by 144
Nefazodone: A Review of its Pharmacology and Clinical Efficacy in the Management of Major Depression
Davis, R., Whittington, R., & Bryson, H. M. (1997) · Drugs · doi:10.2165/00003495-199753040-00006 · Cited by 142
Current perspectives on the development of non-biogenic amine-based antidepressants
Skolnick, P., Legutko, B., Li, X., & Bymaster, F. P. (2001) · Pharmacological Research · doi:10.1006/phrs.2000.0806 · Cited by 140
An AMPA receptor potentiator modulates hippocampal expression of BDNF: an in vivo study
Maćkowiak, M., O’Neill, M. J., Hicks, C. A., Bleakman, D., & Skolnick, P. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00066-7 · Cited by 129
Borsini, F., Evans, K., Jason, K., Rohde, F., Alexander, B., & Pollentier, S. (2002) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2002.tb00219.x · Cited by 125
Sallinen, J., Haapalinna, A., MacDonald, E., Viitamaa, T., Lähdesmäki, J., Rybnikova, E. A., Pelto‐Huikko, M., Kobilka, B. K., & Scheinin, M. (1999) · Molecular Psychiatry · doi:10.1038/sj.mp.4000543 · Cited by 124
Nelson, D. (2004) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007043482606 · Cited by 113
Enhancement of Antidepressant Potency by a Potentiator of AMPA Receptors
Li, X., Witkin, J. M., Need, A. B., & Skolnick, P. (2003) · Cellular and Molecular Neurobiology · doi:10.1023/a:1023648923447 · Cited by 106
Millan, M. J., Seguin, L., Gobert, A., Cussac, D., & Brocco, M. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1770-x · Cited by 106
Self-citationZarate, C. A., Quiroz, J. A., Quiroz, J. A., Manji, H. K., Payne, J. L., Kornstein, S. G., Manji, A. H. K., & MD (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4204 · Cited by 105
Shorter, E., & Tyrer, P. (2003) · BMJ · doi:10.1136/bmj.327.7407.158 · Cited by 105
G protein signaling and the molecular basis of antidepressant action
Donati, R. J., & Rasenick, M. M. (2003) · Life Sciences · doi:10.1016/s0024-3205(03)00249-2 · Cited by 100
Steinberg, R., Alonso, R., Griebel, G., Bert, L., Jung, M., Oury-Donat, F., Poncelet, M., Gueudet, C., Desvignes, C., Fur, G. L., et al. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29250-8 · Cited by 95
Devoto, P., Flore, G., Pira, L., Longu, G., & Gessa, G. L. (2004) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02239.x · Cited by 90
Lerer, B., & Macciardi, F. M. (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702002936 · Cited by 90
Morcuende, S., Gadd, C. A., Peters, M., Moss, A., Harris, E., Sheasby, A., Fisher, A. S., Felipe, C. D., Mantyh, P. W., Rupniak, N. M. J., et al. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02911.x · Cited by 88
Developing novel treatments for mood disorders: accelerating discovery
Tamminga, C. A., Nemeroff, C. B., Blakely, R., Brady, L. S., Carter, C. S., Davis, K. L., Dingledine, R. J., Gorman, J. M., Grigoriadis, D. E., Henderson, D. C., et al. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01470-1 · Cited by 85
Devoto, P., Flore, G., Pira, L., Longu, G., & Gessa, G. L. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.01.018 · Cited by 83
Antidepressant drug treatment induces Arc gene expression in the rat brain
Pei, Q., Zetterström, T., Sprakes, M., Tordera, R. M., & Sharp, T. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00504-9 · Cited by 82
Antiglucocorticoid drugs in the treatment of depression
Reus, V. I., & Wolkowitz, O. M. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.10.1789 · Cited by 82
α2A and α2C‐adrenoceptor regulation in the brain: α2A changes persist after chronic stress
Flügge, G., Kampen, M. V., Meyer, H. H. D., & Fuchs, E. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02510.x · Cited by 80
Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data
Kasper, S. F. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199512004-00005 · Cited by 80
Antidepressant-like effects of NMDA-receptor antagonist injected into the dorsal hippocampus of rats
Padovan, C. M., & Guimarães, F. S. (2003) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2003.09.015 · Cited by 78
Low doses of lithium carbonate reduce melatonin light sensitivity in healthy volunteers
Hallam, K. T., Olver, J. S., Horgan, J., McGrath, C., & Norman, T. R. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004894 · Cited by 77
Gobert, A., & Millan, M. J. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00035-4 · Cited by 72
Self-citationPérez, V., Puigdemont, D., Gilaberte, I., Álvarez, E., & Artigas, F. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200102000-00008 · Cited by 70
Guiard, B. P., Przybylski, C., Guilloux, J., Seif, I., Froger, N., Felipe, C. D., Hunt, S. P., Lanfumey, L., & Gardier, A. M. (2004) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02304.x · Cited by 66
Millan, M. J., Lejeune, F., Nanteuil, G. D., & Gobert, A. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00211.x · Cited by 65
Self-citationCassano, G., & Jori, M. C. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200201000-00004 · Cited by 62
New approaches to developing antidepressants by enhancing monoaminergic neurotransmission
Bymaster, F. P., McNamara, R. K., & Trân, P. V. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.4.531 · Cited by 62
Stone, E. A., Lin, Y., Rosengarten, H., Kramer, H. K., & Quartermain, D. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300222 · Cited by 61
Millan, M. J., Brocco, M., Papp, M., Serres, F., Rochelle, C. D. L., Sharp, T., Péglion, J.-L., & Dekeyne, A. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.062463 · Cited by 60
Self-citationAndreoli, V. M., Caillard, V., Deo, R., RYBAKOWSKI, J. K., & Versiani, M. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200208000-00010 · Cited by 56
Novel strategies for pharmacotherapy of depression
Maubach, K. A., Rupniak, N. M. J., Kramer, M. S., & Hill, R. G. (1999) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(99)80070-2 · Cited by 56
Elucidating the antidepressant actions of substance P (NK1 receptor) antagonists.
Rupniak, N. M. J. (2002) · PubMed · Cited by 53
Pei, Q., Tordera, R. M., Sprakes, M., & Sharp, T. (2003) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.09.017 · Cited by 51
Payne, J. L., Quiroz, J. A., Zarate, C. A., & Manji, H. K. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01676-1 · Cited by 46
Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523
Tottori, K., Miwa, T., Uwahodo, Y., Yamada, S., Nakai, M., Oshiro, Y., Kikuchi, T., & Altar, C. A. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00147-2 · Cited by 46
Possible Role(s) of Neurokinins in CNS Development and Neurodegenerative or Other Disorders
Raffa, R. B. (1998) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(97)00070-5 · Cited by 46
Panocka, I., Massi, M. N., Łapo, I. B., et al. (2001) · Peptides · doi:10.1016/s0196-9781(01)00438-7 · Cited by 46
Treating depression to remission.
Zajecka, J. (2003) · PubMed · Cited by 44
Urani, A., Romieu, P., Portales-Casamar, É., Roman, F. J., & Maurice, T. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1150-y · Cited by 44
Behavioral Pharmacology of AR-A000002, a Novel, Selective 5-Hydroxytryptamine1B Antagonist
Hudzik, T. J., Yanek, M., Porrey, T., Evenden, J. L., Paronis, C. A., Mastrangelo, M., Ryan, C. N., Ross, S. B., & Stenfors, C. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045468 · Cited by 43
The Augmentation Hypothesis for Improvement of Antidepressant Therapy
Kinney, G. G., Taber, M. T., & Gribkoff, V. K. (2000) · Molecular Neurobiology · doi:10.1385/mn:21:3:137 · Cited by 40
Pharmacological principles of antidepressant efficacy
Schatzberg, A. F. (2002) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.399 · Cited by 36
Blendy, J. A., Grimm, L., Perry, D., West-Johnsrud, L., & Kellar, K. J. (1990) · Journal of Neuroscience · doi:10.1523/jneurosci.10-08-02580.1990 · Cited by 34
Lejeune, F., Gobert, A., & Millan, M. J. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02476-9 · Cited by 33
Self-citationRoxindole, a dopamine autoreceptor agonist, in the treatment of major depression
Gründer, G., Wetzel, H., Hammes, E., & Benkert, O. (1993) · Psychopharmacology · doi:10.1007/bf02257418 · Cited by 33
Lejeune, F., & Millan, M. J. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01383-9 · Cited by 31
Self-citationNeurokinin NK1- and NK3-immunoreactive neurons in serotonergic cell groups in the rat brain
Léger, L., Gay, N., & Cespuglio, R. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02543-5 · Cited by 31
Mitchell, S. N., Greenslade, R. G., & Cooper, J. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01469-8 · Cited by 29
Ryckmans, T., Berton, O., Grimée, R., Kogej, T., Lamberty, Y., Pasau, P., Talaga, P. E., & Génicot, C. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00563-2 · Cited by 29
Precision and Comparability of Adverse Event Rates of Newer Antidepressants
Vida, S., & Looper, K. J. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199910000-00005 · Cited by 21
Effects of Antidepressants in Rats Trained to Discriminate Centrally Administered Isoproterenol
Crissman, A. M., & O’Donnell, J. M. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.034686 · Cited by 20
Zhang, H., Huang, Y., & O’Donnell, J. M. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1512-0 · Cited by 19
Norepinephrine transporter splice variants and their interaction with substrates and blockers
Kitayama, S., & Dohi, T. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.08.057 · Cited by 12
Lehr, E. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1199-7 · Cited by 11
The Genomic Approaches to Major Depression
Hong, C., & Tsai, S. (2003) · Current Pharmacogenomics · doi:10.2174/1570160033378295 · Cited by 8
Positive modulators of the AMPA receptor
Grove, S. J. A., Rogers, G. A., & Zhang, M. (2000) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.10.10.1539 · Cited by 6
Comparison of pramipexole, fluoxetine, and placebo in patients with major depression
(2000) · doi:10.1002/(sici)1520-6394(2000)11:2<58::aid-da2>3.0.co;2-h
Cited by
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Self-citationDynorphin, stress, and depression
Knoll, A. T., & Carlezon, W. A. (2010) · Brain Research · doi:10.1016/j.brainres.2009.09.074 · Cited by 465
Effect of vagus nerve stimulation on serotonergic and noradrenergic transmission
Dorr, A. E., & Debonnel, G. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.104166 · Cited by 420
Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders
Kulkarni, S. K., & Dhir, A. (2010) · Phytotherapy Research · doi:10.1002/ptr.2968 · Cited by 367
Albert, P. R., Vahid-Ansari, F., & Luckhart, C. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00199 · Cited by 321
Metadata
- Authors
- Millan, M. J.
- Venue
- European Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 2004-10
- Volume
- 500
- Issue
- 1-3
- Pages
- 371-384
- ISSN
- 0014-2999 (ISSN-L)
- OpenAlex
- W2009334465
- Cited by
- 255
- References
- 114
- FWCI
- 8.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.